## Eyenovia Teams Up with Kinetiq: A Bold Move into Liquid Staking
### A Pioneering Partnership
**LAGUNA HILLS, Calif., June 25, 2025** (GLOBE NEWSWIRE) — **Eyenovia, Inc. (NASDAQ: EYEN)**, a trailblazer in ophthalmic technologies, has taken a notable leap forward by forming a co-branded validator in collaboration with **Kinetiq**, a leading liquid staking protocol designed specifically for the Hyperliquid ecosystem. This partnership marks a significant milestone in Eyenovia’s commitment to innovative onchain engagement.
### Strengthening Network Security
Eyenovia’s latest initiative reflects its strategic acquisition of **1,040,584.5 HYPE**, the native token of Hyperliquid. By establishing this validator, the company contributes directly to the stability and security of the network. Prominent support comes from **Pier Two**, an institutional staking services provider renowned for its state-of-the-art hybrid cloud and bare metal infrastructure, both of which boast rigorous **SOC 2 Type I and Type II certifications**.
### Visionaries Behind the Validator
“Our collaboration with Kinetiq and Pier Two is a strategic stride towards realizing a shared vision for secure, composable, and deeply integrated liquid staking on Hyperliquid,” emphasized **Hyunsu Jung**, Chief Investment Officer of Eyenovia. This sentiment resonates with **Justin Greenberg**, Co-Founder and Chief Technology Officer of Kinetiq, who adds that the **‘Kinetiq x Hyperion’ mainnet validator** is a testament to the convergence of cutting-edge infrastructure, institutional investment, and expert protocol engineering — collectively envisioning **Hyperliquid** as the future of global finance.
### Empowering Investors Through Innovation
The validator initiative represents Eyenovia’s proactive approach to engaging with ecosystem projects. This strategic participation positions investors to reap benefits not just from the underlying asset’s performance, but also from the value created through partnerships and network growth initiatives. Eyenovia is poised as a unique **bridge between public markets and the onchain economy** flourishing on Hyperliquid.
—
### About the Hyperliquid Platform and HYPE Token
#### Hyperliquid: A Blockchain Evolution
**Hyperliquid** is a groundbreaking layer one blockchain (L1) optimized for high-frequency, transparent trading. Each transaction, cancellation, trade, and liquidation occurs within **70-millisecond block times**, catering to the demands of modern finance. Additionally, Hyperliquid is equipped with the **HyperEVM**, a versatile smart contract platform akin to Ethereum, supporting permissionless decentralized financial applications.
#### The Role of HYPE Token
**HYPE**, the native token, plays a pivotal role in the Hyperliquid platform. Users benefit from staked HYPE through reduced trading fees and enhanced referral bonuses. With the blockchain autonomously purchasing and sequestering circulating HYPE, over **25 million HYPE** have already been sequestered as of June 2025, elevating it to the **12th-largest cryptocurrency by market capitalization**.
—
### Eyenovia: Revolutionizing Ophthalmic Care
**Eyenovia, Inc.** stands as a pioneering entity in digital ophthalmic technology, marking history as the first U.S. publicly-listed company building a strategic treasury of Hyperliquid’s HYPE token. This innovative dual approach not only revolutionizes topical eye treatment but also provides shareholders with streamlined access to one of the fastest-growing and highest revenue-generating blockchain ecosystems.
### Upcoming Innovations: The Optejet UFD
Among its impressive technological strides, Eyenovia is developing the **Optejet User Filled Device (UFD)**, designed to administer a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet promises improved compliance, enhanced safety, and greater tolerability, making it particularly beneficial for patients suffering from chronic front-of-the-eye conditions.
For further insights, visit [Eyenovia.com](https://www.eyenovia.com).
—
### Forward-Looking Statements
All statements made herein, aside from historical context, are forward-looking. Such statements encompass our intentions, beliefs, and predictions about future activities. These forecasts hinge on numerous assumptions and are accompanied by risks and uncertainties that could affect actual performance. Eyenovia does not undertake any obligations to update these projections unless required by applicable securities laws.
—
### Investor Relations Contact
For more information, please reach out to:
**Eric Ribner**
**LifeSci Advisors, LLC**
[[email protected]](mailto:[email protected])
(646) 751-4363
